Endo Yoshiro, Tsuchiya Takeru, Omura Takaya, Nakai Kenji, Korosue Kenji, Ishimaru Mutsuki, Ishikawa Yuhiro, Hobo Seiji
Hidaka Training and Research Center, Japan Racing Association, 535-13 Nishicha, Urakawa-cho, Urakawa-gun, Hokkaido 057-0171 Japan.
J Vet Med Sci. 2015 Jan;77(1):75-9. doi: 10.1292/jvms.14-0336. Epub 2014 Oct 29.
The present study evaluated the effects of single-dose marbofloxacin in protecting horses against fever associated with transportation using 48 healthy Thoroughbreds. All horses were premedicated with interferon-α (0.5 U/kg, sublingually, every 24 hr) for 2 days before transportation and on the day of transportation. Horses were randomly assigned to receive marbofloxacin (2 mg/kg, IV, once; MRFX group), enrofloxacin (5 mg/kg, IV, once; ERFX group) or saline (0.9% NaCl) solution (10 ml, IV, once; control group) ≤1 hr before being transportation. Each group contained 16 horses (8 males, 8 females). Horses were transported 1,210 km using commercial vans over the course of approximately 26 hr. Clinical examinations and hematologic analyses were performed on all horses both before and after transportation. Post-transportation neutrophil to lymphocyte ratios were significantly lower in horses in the MRFX group compared with the control horses. The serum amyloid A levels were significantly lower in horses in the MRFX group and ERFX group compared with the control horses. Regarding the post-transportation rectal temperatures, fever was detected in 0 horses and 1 horse in the MRFX and ERFX groups, respectively, whereas fevers exceeding 39.1°C were detected in 2 horses in the control group. Additionally, the number of essential post-transportation treatments provided by veterinarians was reduced 3-fold in the MRFX and ERFX groups compared with the saline group. MRFX provided ERFX-like protection against fever associated with long-distance transportation, yielding significantly better protection than saline. Administration of MRFX just before transportation deserves a further study for efficacy in preventing horse fever associated with transportation.
本研究使用48匹健康纯种马评估了单剂量马波沙星在保护马匹免受与运输相关发热影响方面的作用。所有马匹在运输前2天和运输当天均预先用α-干扰素(0.5 U/kg,舌下给药,每24小时一次)进行预处理。在运输前≤1小时,将马匹随机分配接受马波沙星(2 mg/kg,静脉注射,一次;MRFX组)、恩诺沙星(5 mg/kg,静脉注射,一次;ERFX组)或生理盐水(0.9% NaCl溶液)(10 ml,静脉注射,一次;对照组)。每组包含16匹马(8匹雄性,8匹雌性)。使用商用货车在大约26小时内将马匹运输1210公里。在运输前后对所有马匹进行临床检查和血液学分析。与对照马相比,MRFX组马运输后的中性粒细胞与淋巴细胞比值显著降低。与对照马相比,MRFX组和ERFX组马的血清淀粉样蛋白A水平显著降低。关于运输后的直肠温度,MRFX组和ERFX组分别有0匹马和1匹马检测到发热,而对照组有2匹马检测到体温超过39.1°C。此外,与生理盐水组相比,MRFX组和ERFX组兽医提供的运输后必要治疗次数减少了3倍。MRFX提供了与ERFX类似的针对与长途运输相关发热的保护作用,其保护效果明显优于生理盐水。在运输前即刻给予MRFX在预防与运输相关的马发热方面的疗效值得进一步研究。